Exemplarily, Wang et al. demonstrated that the HPV status can predict the efficacy of PD-1 inhibition in HNSCC patients independent of PD-L1 expression, likely due to an HPV-induced inflamed immune microenvironment [37]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.